Dr. Trivendra Tripathi is a molecular biologist and biotechnology entrepreneur advancing the fields of molecular biology and precision biotechnology. His work focuses on assay design, multiplex qPCR chemistry, and translating molecular platforms into practical applications.

As Founder and CEO of IMDNA and ART BIOTECH, he leads the development of highly specific amplification systems for precise microbial detection and characterization. His approach integrates primer and probe engineering, multiplex assay optimization, analytical performance optimization, and scalable reagent formulation to enable robust, next-generation molecular workflows.

For more than a decade, Dr. Tripathi has directed multidisciplinary research and development programs spanning molecular biology, microbiology, immunology, oncology, and biomarker science. His scientific experience includes roles at Mayo Clinic, B.I.I.R. Baylor Scott & White Research Institute, UNT Health Science Center, Abexxa Biologics, and Ayass Bioscience, where he contributed to assay development, immune profiling, and molecular platform innovation.

As an author of multiple peer-reviewed publications, Dr. Tripathi continues to advance multiplex assay development, molecular platform technologies, and immune-profiling approaches. His work is guided by a clear objective: to bridge molecular science with scalable, application-ready systems and accelerate the deployment of high-performance amplification platforms in research and translational biotechnology. He has received multiple awards recognizing his scientific excellence, innovation, and leadership in the field. 

www.linkedin.com/in/trivendra-tripathi-585b1497